Abstract
Malta, with a population of circa 400,000 and no natural resources, has had to exploit every niche business opportunity to enhance its economic prosperity since gaining independence in 1964. In this respect, current endeavours are focused on the generic pharmaceuticals industry. This sector should form the foundation upon which to build a Mediterranean healthcare centre of excellence. This paper explains why generic pharmaceuticals manufacturers locating in Malta within the next few years will have a distinct competitive advantage. Timing holds the key to success in this fiercely competitive industry. Malta offers a unique blend: the Bolar exemption incorporated into patent legislation; the negligible number of patents registered; and its location between Southern European and North African markets. Together, these bestow the desired timing and attractive marketing opportunities for generics manufacturers.
Get full access to this article
View all access options for this article.